100kDa ์ •๋„ ํฌ๊ธฐ๋ฅผ ๊ฐ€์ง€๋Š” ์•ฝ๋ฌผ ์ข…๋ฅ˜
2025. 5. 15. 18:42
๋ฐ˜์‘ํ˜•

๐Ÿงฌ 100 kDa ์ •๋„์˜ ํฌ๊ธฐ๋ฅผ ๊ฐ€์ง€๋Š” ๋Œ€ํ‘œ์ ์ธ ์•ฝ๋ฌผ ์ข…๋ฅ˜

1. ๋‹จ์ผ ํด๋ก  ํ•ญ์ฒด (Monoclonal Antibodies, mAbs)

  • ๐Ÿ’ก ๋Œ€ํ‘œ ํฌ๊ธฐ: ์•ฝ 150 kDa (full IgG)
  • ๐Ÿ’Š ์˜ˆ์‹œ:
    • Trastuzumab (Herceptin, anti-HER2) – 145 kDa
    • Pembrolizumab (Keytruda, anti-PD-1) – ์•ฝ 149 kDa

→ ํ•˜์ง€๋งŒ fragment ํ˜•ํƒœ๋‚˜ engineered ํ•ญ์ฒด๋Š” ๋” ์ž‘์„ ์ˆ˜ ์žˆ์Œ (~100 kDa ์ˆ˜์ค€)


2. ํ•ญ์ฒด ์กฐ๊ฐ (Antibody fragments)

  • ๐Ÿ’ก ์˜ˆ์‹œ ํฌ๊ธฐ
    • Fab fragment: ์•ฝ 50 kDa
    • scFv: ์•ฝ 25~30 kDa
    • Diabody (์ด์ค‘๊ฒฐํ•ฉ scFv): ์•ฝ 55~60 kDa
    • Tandem scFv (BiTE): ์•ฝ ~100 kDa

๐Ÿ”น Blinatumomab (Blincyto)

  • ํฌ๊ธฐ: ์•ฝ 55 kDa
  • ๊ตฌ์กฐ: CD3 × CD19 bispecific (BiTE)
  • ๐Ÿ’Š ์ž‘์ง€๋งŒ 100 kDa๊ธ‰ ์น˜๋ฃŒ์ œ ์ค‘ ๋Œ€ํ‘œ ์‚ฌ๋ก€

3. ์œตํ•ฉ ๋‹จ๋ฐฑ์งˆ (Fc-fusion proteins)

  • ์˜ˆ: Etanercept (Enbrel, TNF ์ˆ˜์šฉ์ฒด + IgG Fc)
  • ํฌ๊ธฐ: ์•ฝ 150 kDa (ํ•˜์ง€๋งŒ ์ผ๋ถ€๋Š” ์•ฝ 100~120 kDa)

4. ์ด์ค‘ํ•ญ์ฒด ์ค‘ ํฌ๊ธฐ ์กฐ์ ˆ๋œ ๋ฒ„์ „๋“ค

  • ์ผ๋ถ€ ์ด์ค‘ํ•ญ์ฒด๋Š” full IgG ๊ตฌ์กฐ๋ณด๋‹ค ์ž‘๊ฒŒ ์„ค๊ณ„๋˜์–ด ~100 kDa ์ˆ˜์ค€
    • ์˜ˆ: DART, TandAb, Nanobody ์ด์ค‘ํ•ญ์ฒด ๋“ฑ

๐Ÿ“Œ ์ •๋ฆฌ

์•ฝ๋ฌผ ์ข…๋ฅ˜๋Œ€๋žต์  ํฌ๊ธฐ์˜ˆ์‹œ
Full IgG ํ•ญ์ฒด 140~150 kDa Trastuzumab, Pembrolizumab
BiTE 55~60 kDa Blinatumomab
Fc-fusion protein 100~150 kDa Etanercept
Tandem diabody ~100 kDa Engineered BiTE
์ด์ค‘ํ•ญ์ฒด (engineered) 100~120 kDa DART, TandAb ๋“ฑ
 
๋ฐ˜์‘ํ˜•